-
Dec 6, 2024 | 
standard.co.uk | John H Krystal
For over 50 years, psychiatrists focused on dopamine and serotonin pathways for antidepressant treatment. Since the discovery of the antidepressant effects of ketamine roughly 25 years ago, psychiatrists appreciated that depression could also be treated with great efficacy by targeting the glutamate pathway, the main highway for information in the cerebral cortex and a chemical key to learning and memory.
-
Dec 6, 2024 | 
everand.com | John H Krystal
For over 50 years, psychiatrists focused on dopamine and serotonin pathways for antidepressant treatment. Since the discovery of the antidepressant effects of roughly 25 years ago, psychiatrists appreciated that could also be treated with great efficacy by targeting the glutamate pathway, the main highway for information in the cerebral cortex and a chemical
-
Oct 2, 2024 | 
psychiatrictimes.com | John H Krystal
While the US Food and Drug Administration marks a historic moment for schizophrenia treatment, it may take some time to understand where Cobenfy fits in the treatment landscape, says John H. Krystal, MD. Some patients may not want to switch to a new medication even knowing the improved adverse effect profile. Additionally, there are no head-to-head comparisons between Cobenfy and other antipsychotics to illuminate which patients might do best on this new treatment.
-
Oct 1, 2024 | 
psychiatrictimes.com | John H Krystal
John H. Krystal, MD, discusses the newly US Food and Drug Administration-approved schizophrenia treatment, Cobenfy (xanomeline and trospium chloride). This is the first drug with a novel mechanism in decades. It works by selectively targets the M1 and M4 receptors without blocking D2 receptor. As Cobenfy has better tolerability and fewer extrapyramidal symptoms, metabolic adverse effects, and sedation than typical antipsychotic medications, it is hoped patient adherence and outcomes will improve.
-
Sep 20, 2024 | 
psychiatrictimes.com | Heidi Anne Duerr |John H Krystal
CLINICAL CONVERSATIONSIt has been a roller coaster year for psychedelics in psychiatry. On the one hand, there have been safety and efficacy studies promising a brave new world of psychopharmacological options for patients with major depressive disorder, posttraumatic stress disorder (PTSD), generalized anxiety disorder, and psychiatric disorders.
-
Aug 27, 2024 | 
healio.com | John H Krystal |Shenaz Bagha
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. There are two FDA-approved medications for PTSD, both selective serotonin reuptake inhibitors. The FDA has not approved a new medication for PTSD since 2001.
-
Feb 6, 2024 | 00169-0/abstract?rss=yes&sz=64)
biologicalpsychiatryjournal.com | John H Krystal
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
-
Jan 4, 2024 | 
nature.com | Brenda Cabrera-Mendoza |Chadi G Abdallah |John H Krystal |Joel Gelernter |Janitza L. Montalvo-Ortiz |Renato Polimanti
Correction to: Neuropsychopharmacology https://doi.org/10.1038/s41386-023-01747-5, published online 17 October 2023In the original article, the author name Sheila Nagamatsu was incorrectly given as ‘Sheila Nagamastu’. The original article has been corrected. About this articleTamman, A.J.F., Koller, D., Nagamatsu, S. et al. Correction: Psychosocial moderators of polygenic risk scores of inflammatory biomarkers in relation to GrimAge. Neuropsychopharmacol. (2024).
-
Dec 7, 2023 | 
nature.com | Hang Zhou |Rachel L. Kember |Joseph D. Deak |Travis T. Mallard |Jiayi Xu |Emma Johnson | +18 more
AbstractProblematic alcohol use (PAU), a trait that combines alcohol use disorder and alcohol-related problems assessed with a questionnaire, is a leading cause of death and morbidity worldwide. Here we conducted a large cross-ancestry meta-analysis of PAU in 1,079,947 individuals (European, N = 903,147; African, N = 122,571; Latin American, N = 38,962; East Asian, N = 13,551; and South Asian, N = 1,716 ancestries).
-
Dec 7, 2023 | nature.com | Hang Zhou |Rachel L. Kember |Joseph D. Deak |Travis T. Mallard |Jiayi Xu |Emma Johnson | +18 more
AbstractProblematic alcohol use (PAU), a trait that combines alcohol use disorder and alcohol-related problems assessed with a questionnaire, is a leading cause of death and morbidity worldwide. Here we conducted a large cross-ancestry meta-analysis of PAU in 1,079,947 individuals (European, N = 903,147; African, N = 122,571; Latin American, N = 38,962; East Asian, N = 13,551; and South Asian, N = 1,716 ancestries).
